TG Therapeutics, Inc. (NASDAQ:TGTX) Receives $31.83 Average PT from Brokerages

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have received an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $31.83.

TGTX has been the topic of several research reports. B. Riley lifted their price objective on shares of TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. HC Wainwright restated a “buy” rating and set a $49.00 price objective on shares of TG Therapeutics in a research note on Wednesday, September 18th. Finally, The Goldman Sachs Group lifted their target price on TG Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th.

TG Therapeutics Price Performance

Shares of TGTX stock opened at $22.18 on Friday. TG Therapeutics has a twelve month low of $6.46 and a twelve month high of $26.41. The company has a current ratio of 3.58, a quick ratio of 2.83 and a debt-to-equity ratio of 0.58. The stock has a fifty day simple moving average of $22.76 and a two-hundred day simple moving average of $19.05. The stock has a market capitalization of $3.43 billion, a price-to-earnings ratio of 96.43 and a beta of 2.21.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.08. The company had revenue of $73.47 million during the quarter, compared to analyst estimates of $65.92 million. TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. The firm’s revenue for the quarter was up 357.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.34) earnings per share. On average, analysts predict that TG Therapeutics will post 0.13 EPS for the current fiscal year.

Institutional Investors Weigh In On TG Therapeutics

A number of large investors have recently modified their holdings of TGTX. Ashton Thomas Private Wealth LLC acquired a new stake in TG Therapeutics in the 2nd quarter worth approximately $35,000. ORG Wealth Partners LLC purchased a new stake in shares of TG Therapeutics during the third quarter valued at $53,000. DekaBank Deutsche Girozentrale acquired a new position in shares of TG Therapeutics in the 1st quarter valued at $58,000. Lazard Asset Management LLC purchased a new position in TG Therapeutics in the 1st quarter worth $91,000. Finally, nVerses Capital LLC lifted its position in TG Therapeutics by 34.9% during the 2nd quarter. nVerses Capital LLC now owns 5,800 shares of the biopharmaceutical company’s stock worth $103,000 after acquiring an additional 1,500 shares during the period. Hedge funds and other institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.